Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) shares were up 6.6% during trading on Monday . The company traded as high as $8.60 and last traded at $8.78. Approximately 594,146 shares were traded during trading, a decline of 67% from the average daily volume of 1,796,658 shares. The stock had previously closed at $8.24.
Ginkgo Bioworks Price Performance
The stock has a 50-day moving average price of $11.41 and a 200 day moving average price of $9.41. The firm has a market cap of $449.20 million, a price-to-earnings ratio of -0.60 and a beta of 1.23.
Institutional Trading of Ginkgo Bioworks
A number of hedge funds and other institutional investors have recently made changes to their positions in DNA. Bank of America Corp DE increased its position in shares of Ginkgo Bioworks by 780.6% during the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock worth $36,967,000 after purchasing an additional 3,336,964 shares in the last quarter. Forbes J M & Co. LLP increased its position in shares of Ginkgo Bioworks by 461.4% during the fourth quarter. Forbes J M & Co. LLP now owns 701,732 shares of the company's stock worth $6,891,000 after purchasing an additional 576,732 shares in the last quarter. Millennium Management LLC increased its position in shares of Ginkgo Bioworks by 357.4% during the fourth quarter. Millennium Management LLC now owns 670,065 shares of the company's stock worth $6,580,000 after purchasing an additional 523,571 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Ginkgo Bioworks in the 3rd quarter valued at about $4,075,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Ginkgo Bioworks during the 3rd quarter valued at approximately $2,282,000. Institutional investors and hedge funds own 78.63% of the company's stock.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Recommended Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
